دورية أكاديمية
Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy.
| العنوان: | Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. |
|---|---|
| المؤلفون: | Trosman JR; UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), San Francisco, CA 94143, United States.; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143, United States.; Center for Business Models in Healthcare, Glencoe, IL 60022, United States., Weldon CB; UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), San Francisco, CA 94143, United States.; Center for Business Models in Healthcare, Glencoe, IL 60022, United States., Kurian AW; Stanford University, Stanford, CA 94301, United States., Pasquinelli MM; University of Illinois Chicago, Chicago, IL 60607, United States., Kircher SM; Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States., Martin N; LUNGevity Foundation, Bethesda, MD 20814, United States., Douglas MP; UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), San Francisco, CA 94143, United States.; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143, United States., Phillips KA; UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), San Francisco, CA 94143, United States.; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143, United States. |
| المصدر: | Health affairs scholar [Health Aff Sch] 2023 Jun 20; Vol. 1 (1), pp. qxad005. Date of Electronic Publication: 2023 Jun 20 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press on behalf of Project HOPE - The People-To-People Health Foundation, Inc Country of Publication: England NLM ID: 9918627882906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2976-5390 (Electronic) Linking ISSN: 29765390 NLM ISO Abbreviation: Health Aff Sch Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Oxford] : Oxford University Press on behalf of Project HOPE - The People-To-People Health Foundation, Inc., [2023]- |
| مستخلص: | Emerging blood-based multicancer early-detection (MCED) tests may redefine cancer screening, reduce mortality, and address health disparities if their benefit is demonstrated. U.S. payers' coverage policies will impact MCED test adoption and access; thus, their perspectives must be understood. We examined views, coverage barriers, and evidentiary needs for MCED from 19 private payers collectively covering 150 000 000 enrollees. Most saw an MCED test's potential merit for cancers without current screening (84%), but fewer saw its merit for cancers with existing screening (37%). The largest coverage barriers were inclusion of cancers without demonstrated benefits of early diagnosis (73%), a high false-negative rate (53%), and lack of care protocols for MCED-detected but unconfirmed cancers (53%). The majority (58%) would not require mortality evidence and would accept surrogate endpoints. Most payers (64%) would accept rigorous real-world evidence in the absence of a large randomized controlled trial. The majority (74%) did not expect MCED to reduce disparities due to potential harm from overtreatment resulting from an MCED and barriers to downstream care. Payers' perspectives and evidentiary needs may inform MCED test developers, researchers producing evidence, and health systems framing MCED screening programs. Private payers should be stakeholders of a national MCED policy and equity agenda. Competing Interests: Conflicts of interest Please see ICMJE form(s) for author conflicts of interest. These have been provided as supplementary materials. (© The Author(s) 2023. Published by Oxford University Press on behalf of Project HOPE - The People-To-People Health Foundation, Inc.) |
| References: | J Natl Cancer Inst. 2022 Mar 8;114(3):349-352. (PMID: 34450655) JAMA. 2022 Jun 21;327(23):2285-2286. (PMID: 35616934) J Natl Compr Canc Netw. 2015 Mar;13(3):311-8. (PMID: 25736008) Science. 2018 Feb 23;359(6378):926-930. (PMID: 29348365) Cancer. 2022 Feb 15;128 Suppl 4:875-882. (PMID: 35133661) Br J Cancer. 2021 Jan;124(2):315-332. (PMID: 32901135) Cancer. 2022 Feb 15;128 Suppl 4:918-926. (PMID: 35133660) Nat Rev Clin Oncol. 2021 May;18(5):297-312. (PMID: 33473219) Am J Manag Care. 2021 Dec;27(19 Suppl):S347-S355. (PMID: 34870399) Value Health. 2020 May;23(5):551-558. (PMID: 32389219) Br J Cancer. 2021 Nov;125(10):1432-1442. (PMID: 34426664) Cancers (Basel). 2021 Jul 13;13(14):. (PMID: 34298717) Diagnostics (Basel). 2022 May 17;12(5):. (PMID: 35626398) J Natl Compr Canc Netw. 2017 Feb;15(2):219-228. (PMID: 28188191) CA Cancer J Clin. 2008 Jan-Feb;58(1):9-31. (PMID: 18096863) BMC Med Res Methodol. 2013 Sep 18;13:117. (PMID: 24047204) Genet Med. 2020 Feb;22(2):283-291. (PMID: 31501586) JAMA Netw Open. 2022 Mar 1;5(3):e222440. (PMID: 35333365) Curr Oncol. 2014 Jun;21(3):e426-33. (PMID: 24940102) NPJ Precis Oncol. 2018 Oct 29;2:23. (PMID: 30393772) Health Aff (Millwood). 2022 Mar;41(3):383-389. (PMID: 35254936) Genet Med. 2019 May;21(5):1224-1232. (PMID: 31048813) Nature. 2019 Jun;570(7761):385-389. (PMID: 31142840) J Oncol Pract. 2010 Sep;6(5):238-42. (PMID: 21197187) Nat Med. 2021 Jul;27(7):1139-1142. (PMID: 34211183) CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946) Sci Transl Med. 2019 Aug 28;11(507):. (PMID: 31462507) Ann Oncol. 2020 Jun;31(6):745-759. (PMID: 33506766) Health Aff (Millwood). 2006 Jan-Feb;25(1):163-73. (PMID: 19787843) Cancer Epidemiol Biomarkers Prev. 2022 Mar 01;31(3):521-527. (PMID: 34810206) Med Clin North Am. 2020 Nov;104(6):919-938. (PMID: 33099452) Int J Technol Assess Health Care. 2014 Apr;30(2):179-87. (PMID: 24806420) Int J Qual Health Care. 2007 Dec;19(6):349-57. (PMID: 17872937) Health Aff (Millwood). 2014 Jul;33(7):1246-53. (PMID: 25006153) Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):460-468. (PMID: 33328254) Am J Med. 2022 Jul;135(7):e145-e149. (PMID: 35367445) JAMA. 2018 Jun 19;319(23):2379-2380. (PMID: 29710095) Value Health. 2018 Sep;21(9):1062-1068. (PMID: 30224110) Br J Cancer. 2021 Apr;124(9):1475-1477. (PMID: 33558712) Health Aff (Millwood). 2018 May;37(5):694-701. (PMID: 29733705) JCO Precis Oncol. 2018;2:. (PMID: 31073549) Am J Manag Care. 2020 Dec;26(10 Spec No.):SP363. (PMID: 33395237) Cancer Epidemiol Biomarkers Prev. 2022 Mar 1;31(3):512-514. (PMID: 35253043) |
| فهرسة مساهمة: | Keywords: MCED; cancer; insurance coverage and reimbursement; multicancer early detection; payer coverage decision making |
| تواريخ الأحداث: | Date Created: 20240517 Latest Revision: 20240518 |
| رمز التحديث: | 20240518 |
| مُعرف محوري في PubMed: | PMC10986216 |
| DOI: | 10.1093/haschl/qxad005 |
| PMID: | 38756840 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2976-5390 |
|---|---|
| DOI: | 10.1093/haschl/qxad005 |